← Back to Search

Monoclonal Antibodies

DCSZ11 + Pembrolizumab for Advanced Cancer

Phase 1
Recruiting
Research Sponsored by DynamiCure Biotechnology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing DCSZ11, a drug that helps the immune system attack cancer cells by targeting a specific protein. It is aimed at patients with advanced or metastatic solid tumors. The study will determine the best dose and assess its effectiveness both alone and in combination with another drug, pembrolizumab, which has shown efficacy in various cancers.

Who is the study for?
Adults with advanced or metastatic solid tumors, such as colorectal, lung, breast cancer and more, who have tried all other active treatments without success. They must be in a stable condition with good organ function and agree to use contraception. Those with severe heart issues, uncontrolled diseases like pulmonary conditions or infections, recent major surgeries or certain blood clots are excluded.
What is being tested?
The trial is testing DCSZ11 alone and combined with Pembrolizumab in patients with various types of solid tumors that haven't responded to standard therapies. It's an early-phase study looking at how well these drugs work together for treating cancer.
What are the potential side effects?
Potential side effects may include allergic reactions to the drug components, immune-related issues due to monoclonal antibodies like inflammation in organs or skin problems, fatigue from treatment burden and possible complications related to underlying health conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Group I: Phase 1b Dose ExpansionsExperimental Treatment2 Interventions
Dose expansion to further investigate the safety, tolerability, and preliminary evidence of antitumor activity of the combination with pembrolizumab in select tumor indications.
Group II: Phase 1a Dose Escalation MonotherapyExperimental Treatment1 Intervention
Dose escalation to investigate the safety and tolerability of DCSZ11.
Group III: Phase 1a Dose Escalation CombinationExperimental Treatment2 Interventions
Dose escalation to investigate safety and tolerability, and determine DCSZ11 Phase 1b doses in combination with pembrolizumab.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~2850

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Monoclonal antibodies, such as DCSZ11, target specific antigens on the surface of cancer cells, in this case, CD93, which is involved in tumor angiogenesis and growth. By binding to these antigens, these antibodies can inhibit tumor growth, induce cancer cell death, and enhance the immune system's ability to attack cancer cells. This mechanism is crucial for solid tumor patients as it offers a targeted approach, potentially leading to more effective treatments with fewer side effects compared to traditional chemotherapy. Additionally, combining monoclonal antibodies with other therapies can improve overall treatment efficacy and patient outcomes.
Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Find a Location

Who is running the clinical trial?

DynamiCure BiotechnologyLead Sponsor
1 Previous Clinical Trials
5 Total Patients Enrolled

Media Library

DCSZ11 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05785754 — Phase 1
Solid Tumors Research Study Groups: Phase 1a Dose Escalation Combination, Phase 1b Dose Expansions, Phase 1a Dose Escalation Monotherapy
Solid Tumors Clinical Trial 2023: DCSZ11 Highlights & Side Effects. Trial Name: NCT05785754 — Phase 1
DCSZ11 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05785754 — Phase 1
~61 spots leftby Apr 2025